Probiotics: Review of the current state of the problem from the standpoint of clinical pharmacology and evidence-based medicine

Abstract

The use of antibiotics in the treatment of various diseases dramatically changes the quantitative and qualitative compositions of both pathogenic and symbiotic microbiota. Oral and parenteral use of antibacterial drugs affects and changes the quantitative and qualitative compositions of the intestinal microbiota, which subsequently entails changes in the cell development and long-term violations of physiology at all levels of functioning of the macroorganism. This study analyzed available data on modern probiotic drugs, which help improve the normal microbiota in the human body. The results revealed the undoubted effectiveness of various probiotics in acute and antibiotic-associated diarrhea and eradication of Helicobacter pylori.

Keywords

probiotics / microbiota / dysbiosis / eradication / antibiotic-associated diarrhea / clinical pharmacology / evidence-based medicine

References

[1] Kaibysheva VO, Nikonov EL. Probiotics from the standpoint of evidence-based medicine. Russian Journal of Evidence-Based Gastroenterology. 2019;8(3):45–54. EDN: LFBVJW doi: 10.17116/dokgastro2019803145

[2] Кайбышева В.О., Никонов Е.Л. Пробиотики с позиции доказательной медицины // Доказательная гастроэнтерология. 2019. Т. 8, № 3. С. 45–54. EDN: LFBVJW doi: 10.17116/dokgastro2019803145

[3] Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729. doi: 10.1038/s41591-019-0439-x

[4] Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics // Nat Med. 2019. Vol. 25, N. 5. P. 716–729. doi: 10.1038/s41591-019-0439-x

[5] Kim SK, Guevarra RB, Kim YT, et al. Role of probiotics in human gut microbiome-associated diseases. J Microbiol Biotechnol. 2019;29(9):1335–1340. doi: 10.4014/jmb.1906.06064

[6] Kim S.K., Guevarra R.B., Kim Y.T., et al. Role of probiotics in human gut microbiome-associated diseases // J Microbiol Biotechnol. 2019. Vol. 29, N. 9. P. 1335–1340. doi: 10.4014/jmb.1906.06064

[7] Piqué N, Berlanga M, Miñana-Galbis D. Health benefits of heat-killed (tyndallized) probiotics: an overview. Int J Mol Sci. 2019;20(10):2534. doi: 10.3390/ijms20102534

[8] Piqué N., Berlanga M., Miñana-Galbis D. Health benefits of heat-killed (tyndallized) probiotics: an overview // Int J Mol Sci. 2019. Vol. 20, N. 10. P. 2534. doi: 10.3390/ijms20102534

[9] Tkachenko EI, Skazkavaeva EV, Avalueva EB, Sitkin SI. Saccharomyces boulardii (Enterol®) in the practice of the therapist and gastroenterologist. Gastroenterologiya Sankt-Peterburga. 2010;(1):23–24. EDN: YMCEJA (In Russ.)

[10] Ткаченко Е.И., Сказываева Е.В., Авалуева Е.Б., Ситкин С.И. Saccharomyces boulardii (Энтерол®) в практике терапевта и гастроэнтеролога // Гастроэнтерология Санкт-Петербурга. 2010. № 1. С. 23–24 EDN: YMCEJA

[11] Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1): e176–e191. doi: 10.1542/peds.2013-3950

[12] Feizizadeh S., Salehi-Abargouei A., Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea // Pediatrics. 2014. Vol. 134, N. 1. P. e176–e191. doi: 10.1542/peds.2013-3950

[13] Hojsak I, Fabiano V, Pop TL, et al. Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups. Acta Paediatr. 2018;107(6):927–937. doi: 10.1111/apa.14270

[14] Hojsak I., Fabiano V., Pop T.L., et al. Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups // Acta Paediatr. 2018. Vol. 107, N. 6. P. 927–937. doi: 10.1111/apa.14270

[15] Stetsiouk ОU, Andreeva IV. The evidence base and practical approaches to probiotic use in clinical practice: a focus on Lactobacillus rhamnosus GG and Bifidobacterium lactis Вb-12. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):100–118. EDN: QVNQAE Doi: 10.36488/cmac.2019.2.100-118

[16] Стецюк О.У., Андреева И.В. Современные представления об эффективности и практические подходы к применению пробиотиков в клинической практике: фокус на Lactobacillus rhamnosus GG и Bifidobacterium lactis Вb-12 // Клиническая микробиология и антимикробная химиотерапия. 2019. Т. 21, № 2. С. 100–118. EDN: QVNQAE doi: 10.36488/cmac.2019.2.100-118

[17] Ruchkina IN, Fadeeva NA. The role of a combined probiotic in the treatment of lactase deficiency. Terapevticheskii Arkhiv. 2021;93(4): 431–434. EDN: YOITWO doi: 10.26442/00403660.2021.04.200808

[18] Ручкина И.Н., Фадеева Н.А. Роль комбинированного пробиотика в терапии лактазной недостаточности // Терапевтический архив. 2021. Vol. 93, N. 4. P. 431–434. EDN: YOITWO doi: 10.26442/00403660.2021.04.200808

[19] Sugyan NG, Zakharova IN. Bac-Set multiprobiotic: results of Russian and foreign clinical research. Medical Council. 2017;(19): 104–110. EDN: ZQTKXL doi: 10.21518/2079-701X-2017-19-104-110

[20] Сугян Н.Г., Захарова И.Н. Мультипробиотик Бак-Сет. Результаты российских и зарубежных клинических исследований // Медицинский совет. 2017. № 19. С. 104–110. EDN: ZQTKXL doi: 10.21518/2079-701X-2017-19-104-110

[21] Ushkalova EA. Current views on the role of probiotics in the prevention and treatment of different diseases: Focus on Linex. Terapevticheskii Arkhiv. 2014;86(4):117–124. EDN: SVPGZJ

[22] Ушкалова Е.А. Современные представления о роли пробиотиков в профилактике и лечении различных заболеваний: фокус на Линекс // Терапевтический архив. 2014. № 4. С. 117–124. EDN: SVPGZJ

[23] Kornienko EA, Saburova AV. The experience of using l. Acidophilus probiotic in the complex therapy of gastroduodenitis with the syndrome of excessive bacterial growth. Children Infections. 2018;17(3):46–50. EDN: XYUJPF doi: 10.22627/2072-8107-2018-17-3-46-50

[24] Корниенко Е.А., Сабурова А.В. Опыт применения лактосодержащего пробиотика в комплексной терапии гастродуоденитов с синдромом избыточного бактериального роста // Детские инфекции. 2018. Т. 17, № 3. С. 46–50. EDN: XYUJPF doi: 10.22627/2072-8107-2018-17-3-46-50

[25] Ushkalova EA, Gushchina YuSh. Linex forte in the prevention and treatment of gastrointestinal diseases. Terapevticheskii Arkhiv. 2015;(12): 138–144. EDN: VKWGVJ doi: 10.17116/terarkh20158712138-144

[26] Ушкалова Е.А., Гущина Ю.Ш. Линекс форте в профилактике и лечении желудочно-кишечных заболеваний // Терапевтический архив. 2015. № 12. С. 138–144. EDN: VKWGVJ doi: 10.17116/terarkh20158712138-144

[27] Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35(12): 1355–1369. doi: 10.1111/j.1365-2036.2012.05104.x

[28] Videlock E.J., Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea // Aliment Pharmacol Ther. 2012. Vol. 35, N. 12. P. 1355–1369. doi: 10.1111/j.1365-2036.2012.05104.x

[29] Saturio S, Nogacka AM, Alvarado-Jasso GM, et al. Role of Bifidobacteria on infant health. Microorganisms. 2021;9(12):2415. doi: 10.3390/microorganisms9122415

[30] Saturio S., Nogacka A.M., Alvarado-Jasso G.M. et al. Role of Bifidobacteria on infant health // Microorganisms 2021. Vol. 9, N. 12. P. 2415. doi: 10.3390/microorganisms9122415

[31] Kazemi A, Noorbala AA, Azam K, et al. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019;38(2):522–528. doi: 10.1016/j.clnu.2018.04.010

[32] Kazemi A., Noorbala A.A., Azam K., et al. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial // Clin Nutr. 2019. Vol. 38, N. 2. P. 522–528. doi: 10.1016/j.clnu.2018.04.010

RIGHTS & PERMISSIONS

ECO-vector LLC